Facebook
Instagram
Pinterest
Reddit
Tumblr
X
Youtube
Home
About
News
Events
Shop
Directory
Contact Us
Search
Sign in
Welcome! Log into your account
your username
your password
Forgot your password? Get help
Password recovery
Recover your password
your email
A password will be e-mailed to you.
PsyNews.com
Home
About
News
Events
Shop
Directory
Contact Us
Home
Featured
Page 273
Featured
Latest
Latest
Featured posts
Most popular
7 days popular
By review score
Random
The Problems We Will Be Lucky to Have
Pα+ Psychedelic Bulletin #234: Psychedelics After the Midterms; FDA Answers House Psychedelics Caucus; ICER to Review Compass’ Psilocybin; Terran v. Compass Gets Trial Date
Is It Worth It? What Colorado’s Early Experience With Regulated Psychedelic Care Has the Field Asking, and What To Do About It
Compass Says NDA Will Be Filed Within Two Weeks, Declines to Comment on Usona
Podcast: Usona Files Psilocybin Application, We Review 610 Comments Submitted to FDA, and FDA Approves NRx’s Generic Ketamine
Field Trip Health Ltd. Applies to List Its Common Shares on...
PT247 – Julian Vayne – Magic, Prohibition, and New Models for...
Tolerance, Tachyphylaxis, and Psychedelic Drug Action
Psychedelic Bulletin: Poll Shows Support for Psilocybin in the UK; Psychedelics-tinged...
Delix Therapeutics Announces Scientific & Strategic Advisory Board Appointments
PTSF62 – Senate Bill 519, Ketamine, and Psilocybin-producing Cicadas
Op-ed: UK Public Support Psilocybin Research & Rescheduling Despite Government Stance
Mindset Selects its Lead Clinical Candidate, MSP-1014, a Next Generation Psychedelic...
Field Trip Health Ltd. to Commence Trading on the Toronto Stock...
MINDCURE Successfully Completes First Stage of Manufacturing Synthetic Ibogaine for Use...
Load more
